Genprex (GNPX) Interest Expenses (2017 - 2026)
Genprex (GNPX) posted quarterly Interest Expenses of $27110.0 for Q1 2026, up 7.1% year-over-year from $25312.0 in Q1 2025, and down 90.47% quarter-over-quarter from $284386.0 in Q4 2025.
Genprex (GNPX) Interest Expenses (2017 - 2026) Analysis & Trends
Genprex's Interest Expenses history runs 7 years deep, the most recent figure standing at $27110.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 7.1% year-over-year to $27110.0; the TTM figure through Mar 2026 stood at $793989.0 (up 6674.39% YoY), while the FY2025 annual figure was $30.6 million, up 10.87% from the prior year.
- Interest Expenses for Q1 2026 stood at $27110.0, down from $284386.0 in the prior quarter.
- The five-year high for Interest Expenses was $455549.0 in Q3 2025, with the low at -$105848.0 in Q4 2024.
- The 5-year median for Interest Expenses is $27434.0 (2023), against an average of $64465.2.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses slumped 605.46% in 2024, then jumped 1326.71% in 2025.
- Genprex's Interest Expenses stood at $22899.0 in 2022, then retreated by 8.55% to $20941.0 in 2023, then tumbled by 605.46% to -$105848.0 in 2024, then soared by 368.67% to $284386.0 in 2025, then sank by 90.47% to $27110.0 in 2026.
- Business Quant data shows GNPX's Interest Expenses at $27110.0 in Q1 2026, $284386.0 in Q4 2025, and $455549.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,110.00 |
| Mar 31, 2026 | 27,110.00 |
| Dec 31, 2025 | 284,386.00 |
| Dec 31, 2025 | 284,386.00 |
| Sep 30, 2025 | 455,549.00 |
| Sep 30, 2025 | 455,549.00 |
| Jun 30, 2025 | 26,944.00 |
| Jun 30, 2025 | 26,944.00 |
| Mar 31, 2025 | 25,312.00 |
| Mar 31, 2025 | 25,312.00 |
| Dec 31, 2024 | -105,848.00 |
| Dec 31, 2024 | -105,848.00 |
| Sep 30, 2024 | 31,930.00 |
| Sep 30, 2024 | 31,930.00 |
| Jun 30, 2024 | 36,529.00 |
| Jun 30, 2024 | 36,529.00 |
| Mar 31, 2024 | 37,390.00 |
| Mar 31, 2024 | 37,390.00 |
| Dec 31, 2023 | 20,941.00 |
| Dec 31, 2023 | 20,941.00 |